Telegram RegisterThe public register of Telegram

Channel

큐리언트 스토리

@qurient

On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry

1,305subscribers

-1 since we began measuring on 7 August 2026

Risers and fallers across the register · movement among entries of 1,000–3,162.

Register entry

Telegram ID-1001718790662
TypeChannel
Username@qurient
CreatedBetween 1 December 2021 and 31 March 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded7 August 2026
Last confirmed live10 August 2026
Measurements held3
Confirmed unchanged1 time, most recently 10 August 2026
On Telegramt.me/qurient

Growth

1,3051,3061,305.57 August 2026 — 1,306 subscribers7 August 2026 — 1,306 subscribers10 August 2026 — 1,305 subscribers7 August 202610 August 2026
3 measurements spanning 3 days, net -1. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 1,305–1,306 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
10 Aug 2026, 09:031,305-1
7 Aug 2026, 22:321,306no change
7 Aug 2026, 17:591,306first reading

Engagement

20 posts held, back to 15 June 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.

ERR · 30 days
104.7%
avg views ÷ 1,305 subscribers
Avg views / post
1,370
8 posts measured
Reaction rate
1.89%
reactions ÷ views · ER floor
Posts in window
8
of 20 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 3 August 2026
Posts held20 (15 June 20263 August 2026)
Views total10,927
Reactions total207
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken7 Aug 2026, 22:32 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

Reaction mix

522 reactions across 20 posts, in 8 distinct kinds. The most used accounts for 50.6% of them.

Every reaction kind recorded on the sample, most used first
ReactionCountShareShare, drawn
26450.6%
👍17032.6%
🔥458.62%
👏203.83%
🙏163.07%
🕊30.575%
20.383%
🎉20.383%

No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.

Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.

Coverage. Reactions were read on 20 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 522reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.

Measured over the 20 most recent posts we hold, published 15 June 2026 to 3 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.

Recent posts

3 Aug 2026, 23:00 UTC344 views27 reactionsread 7 August 2026
Forwarded from @bio_shinhan

『제약바이오(비중확대) - 엄니버스#3: CDK7, HER2 재편할 루키들』 기업분석부 엄민용, 이호철 ☎️ 02-3772-1546 ▶️ CDK7i가 ADC의 내성, 용량, 부작용 개선으로 새로운 중심된다 이번 자료는 엔허투 처방이 불가한 HER2- 및 HR+ 유방암과 CDKi(CDK 저해제)라는 항암제 기전을 분석한다. 전체 유방암 시장 중 HER2+ 시장은 15%에 불과하며 HER2-, HR+가 70% 이상을 차지한다. 여기서 CDK4/6i가 1차 치료제로 처방되는데, 화이자의 입랜스가 FDA 최초 승인된 이후로 릴리의 버제니오, 노바티스의 키스칼리까지 등장하며 3개 제품 합산 매출은 146억달러를 상회한다. 이는 HER2 양성 유방암 ADC 대표 제품인 다이이찌 산쿄의 엔허투 매출 46억달러의 3배를 넘는 시장이나, 국내에서는 아직 크

16👍7🎉2🔥2

3 Aug 2026, 00:51 UTC853 views23 reactionsread 7 August 2026

큐리언트 이중 페이로드 ADC QP101, AACR 공식 채널서 “새로 떠오르는 치료 전략”으로 소개…글로벌 관심 확인 - AACR D3 발표된 200여 건의 연구 결과 중, 연구소 2곳, 신약 기업 2곳 선정 - 이중 약리 작용으로 더 많은 환자에서 더 지속되는 반응 기대 https://www.hankyung.com/article/202608030955P

👍21👏1🔥1

1 Aug 2026, 00:56 UTC910 views30 reactionsread 7 August 2026

큐리언트 QP101, AACR D3 2026 주목할 연구로 선정 미국암연구학회(AACR)는 공식 블로그를 통해 ‘AACR D3 2026’에서 발표된 200여 건의 연구 가운데 주목할 만한 연구 4건을 선정하고, 연구진 인터뷰와 함께 상세히 소개했습니다. 큐리언트의 차세대 이중 페이로드 ADC QP101이 그중 하나로 선정되며 높은 주목도를 확인했습니다. AACR 공식 블로그 https://www.aacr.org/blog/2026/07/31/from-the-bench-aacr-d3-2026-emerging-therapeutic-strategies-to-inhibit-kras-enhance-adcs-and-tackle-resistance/

21👍4👏4🔥1

28 Jul 2026, 23:19 UTC841 views22 reactionsread 7 August 2026

“ADC 병용 효능 검증 시작”…큐리언트 모카시클립, 트로델비 병용 임상 개시 - 트로델비 병용 삼중음성유방암(TNBC) 임상, 식약처 IND 승인 - 모카시클립의 ADC 병용 전략 본격화 https://www.hankyung.com/article/202607291814P

👍17🔥32

28 Jul 2026, 21:24 UTC809 views18 reactionsread 7 August 2026

ADC ‘탄두 전쟁’ 시작… K-바이오, 新 페이로드 경쟁 시험대 < 제약·바이오 < 과학·헬스 < 기사본문 - IT조선 https://it.chosun.com/news/articleView.html?idxno=2023092166643

13👍4🔥1

26 Jul 2026, 23:24 UTC≈4,350 views24 reactionsread 7 August 2026

큐리언트, ESMO 2026서 모카시클립 임상 1상 완료 결과 공개: 병용 임상 2상의 전략적 근거 제시 - 호르몬 치료제, ADC 등 다양한 병용을 통한 적응증 확장 기반 마련 - 다양한 암에서의 평가 결과를 기반으로 후기 개발 우선순위 확립 https://www.hankyung.com/article/202607276910P

👍23🔥1

22 Jul 2026, 23:18 UTC≈1,500 views26 reactionsread 7 August 2026

큐리언트, AACR D3에서 이중 페이로드 ADC QP101 비임상 데이터 공개 - 엔허투 대비 높은 반응률과 넓은 환자군 치료 가능성 제시 - 영장류 반복투여 독성시험을 통해 우수한 안전성 확보 https://www.hankyung.com/article/202607230605P

18🔥4👏3👍1

21 Jul 2026, 02:21 UTC≈1,320 views37 reactionsread 7 August 2026
Photo

[ESMO Annals of Oncology 7월호 - ADC 페이로드 트렌드 분석] ESMO 학술지에 실린 최근 ADC 페이로드(Payload) 개발 추이입니다. 최근 임상 개발에 진입하는 ADC는 대부분 TOP1 저해제(Camptothecin 계열)를 페이로드로 선택하고 있으며, 이러한 추세는 더욱 강화되고 있습니다. 이는 큐리언트의 Q901에 매우 우호적인 환경입니다. Q901과 Top1 저해제 간의 병용 시너지가 매우 뛰어나, Top1 기반 ADC의 민감도를 향상시키고 치료 효과를 극대화할 수 있기 때문입니다. TOP1 저해제는 암세포에 DNA 손상을 유발하고, CDK7 저해제인 Q901은 RNA 전사와 DNA 손상복구(DDR)를 억제해 이러한 손상이 복구되지 못하도록 합니다. 현재 개발 중인 CDK7 저해제 중, ADC와 병

18👍14🔥3👏2

14 Jul 2026, 01:49 UTC≈8,770 views54 reactionsread 7 August 2026
Photo

⠀ 큐리언트는 다음 주 미국 보스턴에서 열리는 AACR D3 2026(7/21–24)에서 이중 페이로드 ADC 'QP101'의 전임상 유효성 및 영장류 심화 독성 데이터를 공개할 예정입니다. 이번 발표는 CDK7 저해제와 TOP1 저해제를 결합한 QP101이 모든 HER2 표적 ADC 중 best-in-class로 자리잡을 수 있다는 점을 항암제 개발 학계와 산업계에 알리는 계기가 될 것입니다.

👍34🙏133🔥31

6 Jul 2026, 22:26 UTC≈1,700 views26 reactionsread 7 August 2026

< 노바티스, 신규기전 ADC 페이로드 업체 인수 > ADC는 지금까지 주로 전달 기술(항체, 링커, 주사 제형) 중심으로 발전해 왔지만, 궁극적으로 ADC의 효능과 안전성을 좌우하는 핵심 요소인 페이로드에서의 발전은 더뎠습니다. 현재 개발되고 있는 ADC의 대부분은 아직도 수십년된 화학항암제인 Top1저해제를 쓰고 있습니다. 그러나, Top1저해제에 내성이 생긴 환자에게는 비슷한 ADC로는 교차내성때문에 효과가 더이상 없어지기 때문에, 기존의 Top1저해제와는 완전히 독립적인 신규기전의 페이로드가 필요합니다. 큐리언트 자회사 QLi5는 신규 프로테아좀 저해제 페이로드 회사로, M&A 엑싯을 염두에 두고 독일에 설립되었습니다. 고형암뿐만 아니라, 혈액암, 자가면역질환으로 확장가능한 ADC 플랫폼을 구축해가고 있습니다. 신규 페이로드 회

13👍5🔥5🙏3

30 Jun 2026, 00:03 UTC≈1,400 views26 reactionsread 7 August 2026

https://www.hankyung.com/article/202606305538P

18👍5👏2🔥1

29 Jun 2026, 01:01 UTC≈1,280 views26 reactionsread 7 August 2026

[Press Release] 큐리언트, 대한암학회서 모카시클립의 유방암 ‘백본 테라피’ 가능성 제시 - CDK4/6 저해제 내성 극복 및 ADC 병용 두 축으로 유방암 치료의 핵심 약물 잠재력 부각 - 엔허투 재발 모델서 병용 효과 확인으로 엔허투 내성 환자 병용 치료법 제안 http://www.qurient.com/bbs/board.php?bo_table=press_release&wr_id=267

23🔥2👏1

Showing the 12 most recent of 20 posts we hold for @qurient. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Forward network

Republishes

Channels on the register whose posts this channel has forwarded.

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 10 August 2026 — this entry's latest reading, not the date you are reading this.

“큐리언트 스토리” (@qurient), 1,305 subscribers as measured 10 August 2026. Telegram Register, tgregister.com/channel/qurient.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.